Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

Inclusion Criteria: * Histologically confirmed metastatic esophageal tumors with no previous treatment for advanced disease or recurrent disease after previous treatment for at least one year. * At least one measurable lesion according to the RECIST1.1 (Response Evaluation Criteria in Solid Tumors RECIST Version 1.1) criteria. Minimum indicator lesion size: \> 10 mm measured by spiral CT or \>20mm measured by conventional techniques. * Patients aged between 18 and 70 years, inclusive, at the time of acquisition of informed consent * Patients with performance status(ECOG) 0 to 1. * Abnormal hematologic values (WBC ≥ 3.0 x 109/L, Hemoglobin ≥ 10.0g/dl, platelet count ≥ 100 x 109/L) * Creatinine clearance ≥ 60 ml/min, Serum creatinine ≤ 1.5mg/dl * Serum bilirubin ≤ 1.5mg/dl. ALT(Alanine transaminase ), AST(Aspartate Transaminase) ≤ 2.5 x upper normal limit (or ≤ 2.5 x upper normal limit in the case of liver metastases) * Life expectancy ≥ 3 months * Patients who have given written informed consent to participate in this study Exclusion Criteria: * Patients with active multiple cancers; or even if the multiple cancers are metachronous, have a disease-free period of less than 5 years (but excluding cancer in situ and skin cancer) * Serious, uncontrolled, concurrent infection(s) or illness(es) * Patients with no serious concurrent complications (such as heart disease, Intestinal pneumonia) * Patients with brain metastasis * Patients receiving continuous administration of steroids * Patients who have experienced serious drug allergy in the past * Patients with retention of body fluid(pleural effusion, ascites, pericardial effusion) necessitating treatment * Patients who are pregnant and lactating or hope to become pregnant during the study period * Patients with prior Taxane treatment (Paclitaxel) * Others, patients judged by the investigator or coinvestigator to be inappropriate as subject